Mucosis vs Vaxxas

Mucosis

Pioneering needle-free mucosal vaccines for natural and robust immunity

est. 2006

Vaxxas

128 employees · est. 2011 · Brisbane, Australia

Mucosis is the older company (2006 vs 2011).

Side-by-Side Comparison

Metric	Mucosis	Vaxxas
Founded
Founded	2006 older	2011
Headquarters
Headquarters	Not tracked yet	Brisbane, Australia
Employees
Employees	Not tracked yet	128
Industry
Industry	Biotechnology, Health Care	Biotechnology, Health Care, Medical Devices
Funding Stage
Funding Stage	Venture round	Grant
Total Funding
Total Funding	$15.60M	$117.60M
Funding Rounds
Funding Rounds	3	8
Taxonomy
Taxonomy	VaccinesIntranasal DeliveryMucosal VaccinesRespiratory Syncytial VirusMimopath TechnologyClinical-stage +8	VaccinesNeedle-free TechnologyInnovationMedical TechnologyImmunizationPublic Health +2
Website
Website	mucosis.com	vaxxas.com

About Mucosis

Mucosis B.V., founded in 2006, is a Dutch biotechnology company specializing in needle-free mucosal vaccines administered via the nose or mouth. Their flagship product, SynGEM®, an intranasal vaccine targeting respiratory syncytial virus infection, is based on the patented and validated Mimopath® te...

View Full Profile Alternatives

About Vaxxas

Vaxxas, founded in 2011, is a pioneering company in the Biotechnology, Health Care, and Medical Devices sectors, headquartered in Australia. The company is revolutionizing vaccine delivery with its innovative, needle-free technology, designed to enhance the performance of current and next-generation...

View Full Profile Alternatives

Also comparing in this category

Comparing more than these two?

Get Mucosis, Vaxxas and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Mucosis compare?

A PDF of Mucosis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Frequently Asked Questions

Mucosis was founded in 2006. Mucosis B.V., founded in 2006, is a Dutch biotechnology company specializing in needle-free mucosal vaccines administered via the nose or mouth. Their flagship product, SynGEM®, an intranasal vaccine. Vaxxas was founded in 2011, based in Brisbane, Australia, with 128 employees. Vaxxas, founded in 2011, is a pioneering company in the Biotechnology, Health Care, and Medical Devices sectors, headquartered in Australia. The company is revolutionizing vaccine delivery with its in.

Mucosis has raised $15.60M and Vaxxas $117.60M. Latest stage: Mucosis Venture round, Vaxxas Grant.

Both work in Biotechnology and Health Care and list vaccines and innovation among their focus areas.

Compare Mucosis with someone else

Start typing a company name or domain.

Related Comparisons

Vaxxas vs TheraJect, Inc. Mucosis Alternatives Vaxxas Alternatives All Companies All Signals

Compiled from the BounceWatch company index. We last looked at Mucosis on 21 Jun 2024, and Vaxxas on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.